Detection and assessment of co‐association in inhalable drug particles using aerosol time‐of‐flight mass spectrometry |
| |
| Authors: | Anthony New Dave Prime Simeone Zomer David Elder Robert Donovan Evelyn Freney |
| |
| Affiliation: | 1. Novel Analytical Technologies, GlaxoSmithKline, Park Road, Ware SG12 0DP, UK;2. Inhaled Product Development, GlaxoSmithKline, Park Road, Ware SG12 0DP, UK;3. Process Technologies, GlaxoSmithKline, NFSP(S), Harlow SM19 5AW, UK;4. Product Development, GlaxoSmithKline Park Road, Ware SG12 0DP, UK;5. School of Chemistry, University of Edinburgh, West Mains Road, Edinburgh, EH9 3JJ, UK |
| |
| Abstract: | Aerosol Time‐of‐Flight Mass Spectrometry (AToFMS) was used to examine co‐association between two inhaled drugs, fluticasone propionate (FP) and salmeterol xinofoate (SX), in fine aerosolised particles emitted from Seretide®/Advair® inhaled combination products. Principal Component Analysis (PCA) was used to identify fragmentation patterns indicative of either pure or co‐associated particles (particles containing both drugs). A third component of the particles emitted from dry powder inhalers (DPIs), lactose, gave only a very weak mass spectral signal and no interpretable data was acquired for this compound; however, it was not found to interfere with the detection of the two drug substances. High levels of co‐association were found in the emitted doses from both pressurised metered dose inhaler (pMDI) and dry powder inhaler (DPI) products. Copyright © 2008 John Wiley & Sons, Ltd. |
| |
| Keywords: | |
|
|
